BioMedNewsBreaks — Nano-X Imaging Ltd. (NASDAQ: NNOX) Is Building End-to-End Platform for the Future of Medical Imaging

Nanox (NASDAQ: NNOX) is positioning itself as an integrated medical imaging and healthcare technology company, combining proprietary digital X-ray hardware, FDA-cleared AI applications, cloud software, teleradiology, and healthcare IT into an end-to-end platform designed to support earlier disease detection and more efficient care. Its ecosystem includes Nanox.ARC and the next-generation Nanox.ARC X imaging systems, Nanox.AI algorithms for identifying potential signs of chronic disease, Nanox.CLOUD for imaging management, and services through USARAD, Nanox.MARKETPLACE and Nanox Health IT. The company is expanding commercial and clinical activity through relationships with organizations including RadNet, Cedars-Sinai, Corewell Health and Brigham and Women’s Hospital, while also licensing its proprietary X-ray technology to equipment manufacturers. Nanox reported first-quarter 2026 revenue of $4.3 million, up from $2.8 million a year earlier, reflecting contributions across imaging, AI, software, teleradiology and healthcare IT, making the company one to watch as it seeks to broaden access to medical imaging and preventive healthcare.

To view the full article, visit https://ibn.fm/IoHnc

About Nano-X Imaging Ltd.

Nanox is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform. Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care. Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes. For more information, please visit www.Nanox.vision.

NOTE TO INVESTORS: The latest news and updates relating to NNOX are available in the company’s newsroom at https://ibn.fm/NNOX

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN